Prognostic value of various summary measures of prostate-specific antigen (PSA) kinetics for overall survival (OS) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) who failed first-line chemotherapy (TROPIC trial).

被引：0
|
作者：
Legrand, Catherine
Oudard, Stephane
Sartor, A. Oliver
De Bono, Johann Sebastian
Shen, Liji
Machiels, Jean-Pascal H.
机构：
[1] Catholic Univ Louvain, Inst Stat Biostat & Sci Actuarielles, B-1348 Louvain, Belgium
[2] Georges Pompidou European Hosp, Dept Med Oncol, Paris, France
[3] Tulane Canc Ctr, New Orleans, LA USA
[4] Royal Marsden NHS Fdn Trust, Inst Canc Res, Sutton, Surrey, England
[5] Sanofi Aventis, Malvern, PA USA
[6] Catholic Univ Louvain, Ctr Canc, B-1200 Brussels, Belgium
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16010
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Use of speed and extent of PSA response during the first three cycles of docetaxel chemotherapy in metastatic castrate-resistant prostate cancer to predict overall survival
    Goody, R. B.
    Mitchell, D. M.
    McAleese, J.
    O'Sullivan, J. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [22] Sipuleucel-T (sip-T) overall survival (OS) and clinical outcomes by baseline (BL) prostate-specific antigen (PSA) quartiles in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): PROCEED registry.
    Sartor, A. Oliver
    Higano, Celestia S.
    Cooperberg, Matthew R.
    Vogelzang, Nicholas J.
    Dakhil, Shaker R.
    Pieczonka, Christopher Michael
    Vacirca, Jeff
    Concepcion, Raoul S.
    Tutrone, Ronald F.
    Nordquist, Luke T.
    Olsson, Carl A.
    Penson, David F.
    Schnadig, Ian
    Bailen, James L.
    Mehlhaff, Bryan
    Chang, Nancy N.
    Sheikh, Nadeem Anwar
    Brown, Bruce
    Armstrong, Andrew J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [23] Correlation of progression-free survival (PFS) and overall survival (OS) in men with metastatic castration-resistant prostate cancer (CRPC) who failed first-line chemotherapy: Results from the SPARC Trial
    Halabi, S.
    Sartor, O.
    Petrylak, D.
    Sternberg, C. N.
    Witjes, J. A.
    Noursalehi, M.
    McKearn, T. J.
    George, M. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [24] Prognostic associations of prostate-specific antigen (PSA) decline with survival, radiographic response and progression in chemotherapy-naiive men with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide
    Armstrong, A. J.
    Lin, P.
    Higano, C. S.
    Iversen, P.
    Sternberg, C. N.
    Tombal, B.
    Phung, D.
    Parli, T.
    Krivoshik, A.
    Beer, T. M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [25] Prostate-Specific Antigen Changes As Surrogate for Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Second-Line Chemotherapy
    Halabi, Susan
    Armstrong, Andrew J.
    Sartor, Oliver
    de Bono, Johann
    Kaplan, Ellen
    Lin, Chen-Yen
    Solomon, Nicole C.
    Small, Eric J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (31) : 3944 - +
  • [26] Tumor Growth Kinetics Before and After First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: A Prostate-specific Antigen-based Retrospective Analysis
    Colloca, Giuseppe
    Venturino, Antonella
    Guarneri, Domenico
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2018, 41 (03): : 316 - 320
  • [27] Association of prostate-specific antigen (PSA) response and overall survival (OS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the phase 3 ARASENS trial.
    Saad, Fred
    Hussain, Maha H. A.
    Tombal, Bertrand F.
    Fizazi, Karim
    Sternberg, Cora N.
    Crawford, E. David
    Thiele, Silke
    Li, Rui
    Kuss, Iris
    Joensuu, Heikki
    Smith, Matthew Raymond
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [28] Prostate-specific antigen growth rate constant after first-line cytotoxic chemotherapy in metastatic castration-resistant prostate cancer: A monoinstitutional experience
    Colloca, Giuseppe
    Venturino, Antonella
    Addamo, Gianfranco
    Ratti, Riccardo
    Coccorullo, Zaira
    Caltabiano, Graziano
    Viale, Giorgio
    Guarneri, Domenico
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2014, 32 (01) : 42.e1 - 42.e5
  • [29] Prognostic index model (PIM) for overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) without prior chemotherapy treated with abiraterone acetate (AA).
    Ryan, Charles J.
    Kheoh, Thian
    Li, Jinhui
    Molina, Arturo
    De Porre, Peter
    Carles, Joan
    Efstathiou, Eleni
    Kantoff, Philip W.
    Mulders, Peter F. A.
    Saad, Fred
    Griffin, Thomas W.
    Chi, Kim N.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [30] Overall survival (OS) analysis of a phase II study using a pox viral-based vaccine, PSA-TRICOM, in the treatment of metastatic, castrate-resistant prostate cancer (mCRPC): Implications for clinical trial design
    Madan, R. A.
    Gulley, J. L.
    Dahut, W. L.
    Tsang, K. Y.
    Steinberg, S. M.
    Schlom, J.
    Arlen, P. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345